Science
Featuring an interview with Dr Sara M Tolaney, including the following topics: Role of the Breast Cancer Index® in predicting benefit from extended aromatase inhibitor therapy for hormone receptor (HR)-positive breast cancer (0:00) ADAPT HR-positive/HER2-negative trial: Prognostic utility of genomic assays, clinical factors and response to endocrine therapy for patients with high-risk luminal breast cancer (5:43) De-escalation of neoadjuvant chemotherapy in the treatment of early breast cancer — Clinical outcomes from the ADAPT HR-negative/HER2-positive trial (9:49) Effect of dose escalation on the tolerability of neratinib — Results from the CONTROL study (15:02) Phase II GeparNuevo study: Addition of durvalumab to neoadjuvant anthracycline/taxane therapy for early triple-negative breast cancer (17:13) Neoadjuvant talazoparib for patients with HER2-negative early breast cancer with germline BRCA1/2 mutations — Results from the Phase II NEOTALA study (21:53) Results from the Phase III OlympiA trial assessing adjuvant olaparib for patients with high-risk HER2-negative early breast cancer with germline BRCA1/2 mutations (23:02) Updated survival results from Phase III studies of CDK4/6 inhibitors in combination with hormonal therapy for HR-positive, HER2-negative advanced breast cancer (27:23) Long-term outcomes with alpelisib and fulvestrant for patients with HR-positive advanced breast cancer with PIK3CA mutations (30:58) Trastuzumab with endocrine therapy or chemotherapy as first-line treatment for HR-positive, HER2-positive metastatic breast cancer: Results from the SYSUCC-002 trial (33:20) Subgroup analysis of the DESTINY-Breast01 trial: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer and stable brain metastases (36:29) BEGONIA: A Phase Ib/II study of durvalumab combinations for advanced triple-negative breast cancer (39:49) CME information and select publications